303 related articles for article (PubMed ID: 9234928)
1. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
2. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.
Janicek MF; Sevin BU; Nguyen HN; Averette HE
Gynecol Oncol; 1995 Oct; 59(1):87-92. PubMed ID: 7557622
[TBL] [Abstract][Full Text] [Related]
3. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
7. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
8. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
9. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.
Kassis ES; Zhao M; Hong JA; Chen GA; Nguyen DM; Schrump DS
J Thorac Cardiovasc Surg; 2006 Feb; 131(2):298-306. PubMed ID: 16434257
[TBL] [Abstract][Full Text] [Related]
10. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Skilling JS; Squatrito RC; Connor JP; Niemann T; Buller RE
Gynecol Oncol; 1996 Jan; 60(1):72-80. PubMed ID: 8557231
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
Girnita L; Girnita A; Brodin B; Xie Y; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Cancer Res; 2000 Sep; 60(18):5278-83. PubMed ID: 11016658
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines.
Reynolds RK; Hu C; Baker VV
Gynecol Oncol; 1998 Aug; 70(2):202-9. PubMed ID: 9740691
[TBL] [Abstract][Full Text] [Related]
15. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
16. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines.
Steele C; Cowsert LM; Shillitoe EJ
Cancer Res; 1993 May; 53(10 Suppl):2330-7. PubMed ID: 7683572
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
[TBL] [Abstract][Full Text] [Related]
18. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.
Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E
Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
Rubenstein M; Tsui P; Guinan P
Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y
Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
